Fig. 4

SOP enhances β-catenin degradation by ESRRG in gastric cancer cells. a AGS and SGC7901 cells were treated with or without 3 μM SOP for 24 h. phosphorylated β-catenin^{(Ser33/37/Thr41)} and β-catenin expression were determined by western blot. b phosphrylated β-catenin^{(Ser33/37/Thr41)} and β-catenin expression in cellular fractions of AGS cells (a) were detected. c AGS cells were treated with 1 μM CHX alone or in combination with 3 μM SOP for the indicated times and β-catenin expression were determined by western blot. (D) AGS cells were treated with 1 μM CHX alone or in combination with 3 μM SOP for 5 h, β-catenin expression in cellular fractions were detected by western blot. e AGS cells were treated with with 10 μM MG132 alone or in combination with 3 μM SOP for 24 h, expression of indicated proteins were determined by western blot. f AGS cells transfected with siRNA non-target control (siNC) or ESRRG siRNA were treated with or without 3 μM SOP for 24 h, ESRRG and β-catenin expression were determined by western blot. Full-length blots/gels are presented in Supplementary Figure S6 and band density of target proteins was quantified by ImageJ software (Version 6.0, Media Cybernetics, Inc.) as presented in Figure S2. The results are representatives of at least 3 independent experiments. Abbreviation: SOP, Sophoridine; CHX: cycloheximide